Mark O'Hara

10PUBLICATIONS
124CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 30, 2026
Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma.

Eileen M O'Reilly, Christopher R Cabanski, Jaclyn P Lyman

|Jan 19, 2026
Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma.

Jacob E Till, Ofer Gal-Rosenberg, Sophia G Giliberto

|Jan 07, 2026
IL10R Inhibition Induces Neutrophil Tumoricidal Activity.

Danny N Khalil, Ricardo Gomez, Amit Regev

|Mar 06, 2025
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.

Lakshmi Rajdev, Gentry G King, Christopher H Lieu

|Oct 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.

Mark H O'Hara, Opeyemi Jegede, Mark A Dickson

|Aug 09, 2024
KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.

Minh T Than, Mark O'Hara, Ben Z Stanger

Pageof 2

Frequent Collaborators

4 joint publications

Jacob E Till

4 joint publications

Erica L Carpenter

3 joint publications

Kim A Reiss

3 joint publications

Thomas Karasic